bit bio

#Biotech #bit bio #Drug discovery #Human disease models

Bit.bio to develop human cell models for drug discovery 

Biotech company bit.bio has closed a $50 million Series C funding round to scale human cell models for drug discovery.  The company aims to use the funding to accelerate the development of, and access to, its products, scale its operations globally, expand into the multi-billion toxicology market, bolster its… Read More

#Business & Investment #News

Human cell
#AI / data analytics / healthtech / informatics #bit bio #CAR-T #Cell therapy #Data security #Stem cells

New podcast: Overcoming barriers to patient access

This is the latest episode of the free DDW narrated podcast, titled “Overcoming barriers to patient access”, which covers two articles written for DDW Volume 25 – Issue 1, Winter 2023/24. They are called: “Scaling up: The need for human cells to give better access to cell therapies” and… Read More

#News

#Assays #bit bio #Disease modelling #Drug discovery #iPSC #iPSC-derived cells

Listicle: Get the best out of human iPSC derived cells in your assays

Watch this DDW listicle, 5 ways to get the best out of human iPSC-derived cells in your assays from bit.bio, for free now. Transitioning to human iPSC-derived cells can open powerful opportunities for drug discovery, neuroscience, and disease modelling, but success depends on how you handle and culture them. Read More

#News

#bit bio #CAR-T #CRISPR #Drug development #Drug discovery #Stem cells #Synthetic biology #Synthetic DNA

New podcast: An overview on the impact of synthetic biology

This is the latest episode of the free DDW narrated podcast, titled “An overview on the impact of synthetic biology”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Synthetic biology: Impacting drug discovery” and “Synthetic biology: Innovating in drug… Read More

#News

#bit bio #EU patent #iPSC #Patent Law #Pluripotent stem cells

bit.bio wins patent defence for opti-ox technology

bit.bio has successfully defended its foundational European patent for opti-ox, a technology the company says enables deterministic forward programming of pluripotent stem cells (PSCs). Following an anonymous opposition filed on 5 January 2023 and a public hearing on 25 September 2024, the European Patent Office’s (EPO)… Read More

#Business & Investment #News

Cells under a microscope
#bit bio #CAR-T #Cell therapy #Interview #iPSC #Stem cells

Scaling up: The need for human cells to give better access to cell therapies

Reece Armstrong speaks to Kathryn Golden, SVP Technical Operations and Manufacturing, bit.bio, about novel technologies, and methods to manufacture human cells for therapies so more patients can access these treatments. Cell therapies have emerged as transformative and potentially curative treatments across a range of disease… Read More

#Exclusive Content

CRISPR-ready neurons
#bit bio #CRISPR #Gene editing #Genetics / genomics #Neurology #Neuroscience

New CRISPR-ready neurons could democratise genomics

bit.bio has launched the first offering from its new product range ioCRISPR-Ready Cells, which allow research and drug discovery scientists to knockout any gene of interest in glutamatergic neurons. CRISPR-Ready ioGlutamatergic Neurons are first-in-class stem-cell derived human neurons containing a constitutively-expressed Cas9 nuclease for gene knockouts… Read More

#News

Treg cells
#Bayer #bit bio #BlueRock Therapeutics #Collaboration #iPSC #T cell activation

BlueRock and bit.bio sign Treg therapies discovery deal

Bayer subsidiary BlueRock Therapeutics, and bit.bio have announced a collaboration to discover and manufacture regulatory T cell (Treg) based therapies. Under the terms of the agreement, bit.bio will use its machine learning discovery platform to identify transcription factor (TF) combinations for reprogramming iPSCs into Tregs. Read More

#News

#bit bio #Cell programming #iPSC #Synthetic biology #US patent

bit.bio secures foundational US patent for opti-ox

bit.bio has secured a foundational US patent for opti-ox, its precision cell programming and manufacturing technology. opti-ox uses a dual genomic safe harbour approach to cell programming, and the granted US patent covers the use of opti-ox to deterministically activate genetic code in any eukaryotic (cell… Read More

#Business & Investment #News

Gene editing
#bit bio #CRISPR #Drug discovery #Stem cells #Synthetic biology #Synthetic DNA

Synthetic biology: Impacting drug discovery

Listen to this article on the DDW Podcast: Mark Kotter, Founder and CEO of bit.bio, talks with Reece Armstrong about different approaches to synthetic biology and its applications in programming stem cells into mature, functional human cells for drug discovery and the creation of next… Read More

#Exclusive Content

Microglia
#bit bio #iPSC #Poster #Stem cells

Poster: Accelerated production of functional microglia

Download this new scientific Poster from bit.bio, just revealed at ISSCR 2023. You will discover: How precision reprogramming generates consistent, functional human microglia (ioMicroglia) from iPSCs in just 10 days Independent validation that ioMicroglia undergo phagocytosis of both E. coli particles and amyloid beta particles Independent validation… Read More

#News

ioDisease Model Cells
#bit bio #Cell coding #CRISPR-Cas9 #Gene editing

bit.bio launches custom disease model cells

Cell coding company bit.bio has launched a new disease model cell offering enabling scientists to commission disease-relevant mutation of interest.   The company’s new Custom ioDisease Model Cells offering lets scientists choose the disease-relevant mutation they’re interested in. The disease-relevant mutation is engineered into bit.bio’s human ioWild Type … Read More

#News